COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles (JUVE_COSMO_1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01212809
Recruitment Status : Completed
First Posted : October 1, 2010
Last Update Posted : September 12, 2011
Information provided by (Responsible Party):
Steven Fagien, Fagien, Steven, M.D., PA

Brief Summary:
This study is being done to evaluate the differences in the performance of two well known injectable dermal fillers commonly used for the cosmetic treatment of age lines above the lips and on the cheeks when compared to each other in the same patient. The products being tested are Juvéderm® Ultra and CosmoDerm® 1.

Condition or disease Intervention/treatment Phase
Intrinsic Aging of Skin Device: Juvéderm Ultra Device: Cosmoderm 1 Phase 4

Detailed Description:
This is a single center, prospective, open label, randomized, comparative, split-face study in adult females or males aged 25 to 70 years seeking treatment with reconstituted Juvéderm® Ultra and CosmoDerm® 1 human-based collagen implant for moderate to severe vertical lip rhytids and/or radial cheek lines.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open Label, Randomized, Comparative, Split-Face Study Evaluating Reconstituted JUVÉDERM® Ultra Injectable Gel Versus COSMODERM® 1 Human Based Collagen Implant for the Treatment of Vertical Lip Rhytids and Radial Cheek Lines
Study Start Date : September 2010
Actual Primary Completion Date : April 2011
Actual Study Completion Date : June 2011

Arm Intervention/treatment
Active Comparator: Juvéderm Ultra
Juvéderm Ultra injection
Device: Juvéderm Ultra
Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
Other Name: Juvéderm Ultra injectable gel (crosslinked hyaluronic acid)

Active Comparator: Cosmoderm 1
Cosmoderm 1 injection
Device: Cosmoderm 1
Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
Other Name: Cosmoderm 1 human-based collagen implant

Primary Outcome Measures :
  1. Global Assessment of Improvement by Physician Evaluator [ Time Frame: 3 days, 2 and 6 weeks, 4 and 6 months ]
    Global Assessment of Improvement by Physician Evaluator, including Facial Photographs, Vertical Lip Rhytids and Radial Cheek Line Rating Scales

Secondary Outcome Measures :
  1. Patient Efficacy, Pain, Adverse Event Assessments [ Time Frame: 3 days, 2 and 6 weeks, 4 and 6 months ]
    • Facial Line Outcomes (FLO-11 version 1.0) Questionnaire - Patient
    • Self-Perception of Age (SPA version 2.0) measure - Patient
    • Global Assessment of Improvement - Patient
    • Self-Rated Pain Assessment Scale (0-10 point rating scale)
    • Treatment-emergent adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult females or males, aged 25 to 70 years;
  • Subjects must be seeking treatment with Juvéderm Ultra and CosmoDerm 1 injections for vertical lip rhytids or radial cheek lines;
  • Subjects must have one or more moderate to severe vertical lip rhytids and/or moderate to severe radial cheek lines based on the physician evaluator assessment (0-3 scale);
  • Women must either be of non-childbearing potential (i.e., surgically sterilized or post-menopausal) or if of childbearing potential, must not be pregnant (as documented by a negative urine pregnancy test at the baseline examination) or lactating and must be practicing a medically acceptable method of birth control;
  • Subjects must be willing and able to provide written informed consent;
  • Subjects must be willing and able to follow the procedures outlined in this protocol.

Exclusion Criteria:

  • Female subjects who are pregnant (positive urine pregnancy test) or who have an infant they are breast-feeding or who are of childbearing potential and not practicing a reliable method of birth control;
  • Previous Botox treatment to the lower two-thirds of the face within the past 6 months for subjects who will have injections into their radial cheek lines. Note: this exclusion criterion does not apply to subjects who only will have injections into lip rhytids unless the previous Botox treatment was administered within the past 6 months to the upper lip region;
  • Previous semipermanent injectable filler therapy to the mid-lower face within the past year or any prior history of permanent filler therapy injection to the mid-lower face;
  • Prior cosmetic procedures (i.e., facelift, etc.) or visible scars that may affect evaluation of response and/or quality of photography in the opinion of the investigator;
  • Known allergy or sensitivity to any of the treatment injections or their components, including known or suspected lidocaine hypersensitivity;
  • Known severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies;
  • Subjects with an infection at an injection site or systemic infection (in this case, postpone study entry until one week following recovery);
  • Subjects requiring treatment with major anticoagulants (such as Coumadin) or antiplatelets (such as Plavix) during the study; low-dose aspirin treatment or antiinflammatory medication with potential anticoagulant or antiplatelet effect may be allowed at the investigator's discretion;
  • Concurrent participation in an investigational drug or device study or participation within 30 days of study start;
  • Subjects are not to undergo any additional cosmetic procedures during the study period;
  • Subjects are not to change use of any facial products up to 6 months prior to enrollment and during study period;
  • Subjects with a history of poor cooperation, non-compliance with medical treatment, or unreliability.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01212809

Layout table for location information
United States, Florida
Steven Fagien, MD, PA
Boca Raton, Florida, United States, 33431
Sponsors and Collaborators
Steven Fagien
Layout table for investigator information
Principal Investigator: Steven Fagien, MD Steven Fagien, MD, PA
Layout table for additonal information
Responsible Party: Steven Fagien, Principal Investigator, Fagien, Steven, M.D., PA Identifier: NCT01212809    
Other Study ID Numbers: JUVE_COSMO_1-10-01
First Posted: October 1, 2010    Key Record Dates
Last Update Posted: September 12, 2011
Last Verified: September 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents